0 stringlengths 12 494 | embeddings listlengths 384 384 |
|---|---|
the prespeci fied end point of end-stage\nkidney disease alone by 32% (HR 0.68[95% CI 0.54 –0.86]). Canagli flozin was\nadditionally found to have a lower riskof the composite of cardiovasculardeath, MI, or stroke (HR 0.80 [95% CI0.67–0.95]) as well as lower risk of hos-\npitalizations for heart failure (HR 0.61[95% CI 0... | [
-0.008615793660283089,
0.08022656291723251,
-0.06679942458868027,
0.002746183192357421,
-0.020450949668884277,
0.033077314496040344,
-0.0316600427031517,
0.06654639542102814,
-0.00004719053686130792,
-0.018785392865538597,
-0.005719299428164959,
-0.021904975175857544,
-0.051264647394418716,
... |
ite of cardiovascular death or hospitali-zation for heart failure (HR 0.69 [95%\nCI 0.57 –0.83]). In terms of safety, no\nsignificant increase in lower-limb ampu-\ntations, fractures, AKI, or hyperkalemia\nwas noted for canagli flozin relative to\nplacebo in CREDENCE. An increased risk\nfor diabetic ketoacidosis was note... | [
0.035533607006073,
0.036802131682634354,
-0.05316874012351036,
-0.015319311991333961,
-0.040400125086307526,
-0.013185853138566017,
0.012842398136854172,
0.10159968584775925,
-0.035137273371219635,
0.012201215140521526,
-0.014632388018071651,
0.030688393861055374,
-0.011688998900353909,
0.... |
for diabetic ketoacidosis was noted, how-\never, with 2.2 and 0.2 events per 1,000patient-years noted in the canagli flozin\nand placebo groups, respectively (HR 10.80\n[95% CI 1.39– 83.65]) (247).\nThe Dapagli flozin Effect on Cardiovascu-\nlar Events-Thrombosis in Myocardial Infarc- | [
-0.02567950263619423,
0.0480240136384964,
-0.07419656217098236,
0.023074176162481308,
-0.05027550831437111,
-0.07542935013771057,
-0.007099103182554245,
0.11032935231924057,
0.051222044974565506,
-0.04591233655810356,
-0.019475499168038368,
0.01451566070318222,
-0.09225603938102722,
0.0107... |
lar Events-Thrombosis in Myocardial Infarc-\ntion 58 (DECLARE-TIMI 58) trial wasanother randomized, double-blind trial that\nassessed the effects of dapaglifl ozin versus\nplacebo on cardiovascular and renal out-\ncomes in 17,160 people with type 2 diabe-tes and established ASCVD or multiple risk\nfactors for ASCVD (249... | [
-0.0666569173336029,
-0.003270978108048439,
-0.06506912410259247,
0.022069662809371948,
0.0463421456515789,
0.010675046592950821,
-0.07105123996734619,
0.1708770990371704,
0.06356196105480194,
0.0030284340027719736,
-0.017212795093655586,
0.012144324369728565,
-0.11162952333688736,
-0.0092... |
factors for ASCVD (249). Study participants\nhad a mean age of 64 years, with /C2440%\nof study participants having establishedASCVD at baseline— a characteristic of this\ntrial that differs from other large cardiovas-cular trials where a majority of participantshad established cardiovascular disease.DECLARE-TIMI 58 me... | [
0.04679349064826965,
-0.02390499971807003,
-0.07611242681741714,
0.045732513070106506,
0.003396660787984729,
0.05308714881539345,
-0.09137926995754242,
0.12636825442314148,
-0.018400514498353004,
0.023347502574324608,
0.053765296936035156,
-0.0432625487446785,
-0.041341401636600494,
-0.005... |
teria for noninferiority to placebo with re-spect to major adverse cardiovascularevents but did not show a lower rate of ma-jor adverse cardiovascular events when\ncompared with placebo (8.8% in the dapa-\ngliflozin group and 9.4% in the placebo\ngroup; HR 0.93 [95% CI 0.84 –1.03]; P=\n0.17). A lower rate of cardiovascu... | [
-0.01146298460662365,
0.005865182727575302,
-0.07763760536909103,
0.016597850248217583,
-0.03669244050979614,
-0.05125735327601433,
-0.03695574775338173,
0.12107934802770615,
0.017725124955177307,
-0.04106764495372772,
0.01804620958864689,
0.002946859458461404,
-0.07083885371685028,
0.0018... |
0.17). A lower rate of cardiovascular death\nor hospitalization for heart failure was\nnoted (4.9% vs. 5.8%; HR 0.83 [95% CI0.73– 0.95]; P= 0.005), which re flected a\nlower rate of hospitalization for heart failure(HR 0.73 [95% CI 0.61 –0.88]). No difference\nwas seen in cardiovascular death betweengroups.\nIn the Dapa... | [
-0.0032969568856060505,
0.0726047232747078,
-0.041219983249902725,
0.007092699874192476,
-0.01608423888683319,
-0.03758968412876129,
-0.035876449197530746,
0.11635784804821014,
-0.03609457239508629,
-0.040128663182258606,
0.033224307000637054,
0.005999431945383549,
-0.014563188888132572,
-... |
In the Dapagli flozin and Prevention of\nAdverse Outcomes in Chronic KidneyDisease (DAPA-CKD) trial (250), 4,304\nindividuals with CKD (UACR 200 –\n5,000 mg/g and eGFR 25– 75 mL/min/\n1.73 m\n2), with or without diabetes,\nwere randomized to dapagli flozin 10 mg\ndaily or placebo. The primary outcome | [
-0.058513544499874115,
0.036035217344760895,
-0.014269521459937096,
-0.009029732085764408,
-0.10879548639059067,
-0.09190870821475983,
-0.007281730882823467,
0.10195741802453995,
0.00532147753983736,
-0.02902725152671337,
-0.05073411390185356,
0.04999237507581711,
-0.06489266455173492,
-0.... |
daily or placebo. The primary outcome\nwas a composite of sustained decline ineGFR of at least 50%, end-stage kidneydisease, or death from renal or cardio-\nvascular causes. Over a median follow-\nup period of 2.4 years, a primary out-come event occurred in 9.2% of partici-pants in the dapagli flozin group and\n14.5% of... | [
-0.020954953506588936,
0.032430846244096756,
-0.023542197421193123,
0.021180082112550735,
-0.046492163091897964,
-0.07552191615104675,
-0.015314137563109398,
0.14141137897968292,
0.08446118980646133,
-0.040129631757736206,
-0.021828895434737206,
0.05354826897382736,
-0.047978468239307404,
... |
14.5% of those in the placebo group. The\nrisk of the primary composite outcome\nwas signifi cantly lower with dapaglifl ozin\ntherapy compared with placebo (HR 0.61[95% CI 0.51– 0.72]), as were the risks for | [
0.04517361894249916,
0.032738689333200455,
-0.10382138937711716,
0.056972701102495193,
-0.007520995102822781,
-0.06877123564481735,
0.005073314532637596,
0.20792856812477112,
0.041092194616794586,
-0.04025391861796379,
-0.0064035626128315926,
0.030051659792661667,
-0.04252117872238159,
-0.... |
a renal composite outcome of sustainedd e c l i n ei ne G F Ro fa tl e a s t5 0 % ,e n d -stage kidney disease, or death from renalcauses (HR 0.56 [95% CI 0.45 –0.68]), and\na composite of cardiovascular death orhospitalization for heart failure (HR 0.71[95% CI 0.55– 0.92]). The effects of dapa-\ngliflozin therapy were ... | [
-0.060494404286146164,
0.001718810643069446,
-0.005517248529940844,
-0.039036042988300323,
-0.04680616408586502,
-0.055428918451070786,
-0.04305284097790718,
0.11761324852705002,
-0.004663194064050913,
-0.0616024024784565,
-0.08821792900562286,
-0.0097921472042799,
-0.008071422576904297,
0... |
gliflozin therapy were similar in individu-\nals with and without type 2 diabetes.\nResults of the Dapagli flozin and Pre-\nvention of Adverse Outcomes in HeartFailure (DAPA-HF) trial, the Empagli flozin\nOutcome Trial in Patients With ChronicHeart Failure and a Reduced Ejection\nFraction (EMPEROR-Reduced), Empagli-\nflozi... | [
-0.059222329407930374,
0.028350431472063065,
-0.03153735399246216,
0.047428082674741745,
-0.09606155008077621,
-0.048064760863780975,
-0.010616088286042213,
0.12225855886936188,
-0.030848635360598564,
-0.07184965908527374,
-0.0013403978664427996,
0.035433683544397354,
-0.083087258040905,
-... |
flozin Outcome Trial in Patients With\nChronic Heart Failure With PreservedEjection Fraction (EMPEROR-Preserved),\nEffects of Dapagli flozin on Biomarkers,\nSymptoms and Functional Status indiabetesjournals.org/care Cardiovascular Disease and Risk Management S203\n©AmericanDiabetesAssociation | [
-0.03515743091702461,
0.022064557299017906,
-0.06537990272045135,
0.025655357167124748,
-0.023637086153030396,
-0.0019507500110194087,
-0.057687874883413315,
0.07823479920625687,
-0.0551430806517601,
-0.056198686361312866,
-0.015100555494427681,
-0.026990287005901337,
-0.08611948788166046,
... |
Patients With PRESERVED Ejection Frac-\ntion Heart Failure (PRESERVED-HF), andDapagli flozin Evaluation to Improve the\nL i v e so fP a t i e n t sw i t hP r e s e r v e dE j e c t i o nFraction Heart Failure (DELIVER), which\nassessed the effects of dapagli flozin and\nempagli flozin in individuals with estab-\nlished he... | [
-0.04022658243775368,
-0.002228786237537861,
-0.010326726362109184,
0.0030795088969171047,
-0.019267605617642403,
0.008038868196308613,
-0.0629609003663063,
0.08801443874835968,
-0.05491137132048607,
-0.05220146104693413,
-0.017296046018600464,
-0.009101933799684048,
-0.06573379784822464,
... |
lished heart failure (14,242,251– 253), are\ndescribed below in\nGLUCOSE -LOWERING THERA-\nPIES AND HEART FAILURE .\nThe Evaluation of Ertugli flozin Ef ficacy\nand Safety Cardiovascular Outcomes\nTrial (VERTIS CV) (254) was a random-ized, double-blind trial that established\nthe effects of ertugli flozin versus placebo | [
0.014892497099936008,
0.021496549248695374,
-0.057977695018053055,
0.011816533282399178,
0.018567664548754692,
0.009803012013435364,
-0.04695716127753258,
0.16178768873214722,
-0.03940877690911293,
-0.047927938401699066,
-0.04151223599910736,
0.03882243111729622,
-0.028618572279810905,
-0.... |
the effects of ertugli flozin versus placebo\non cardiovascular outcomes in 8,246 peo-\nple with type 2 diabetes and establishedASCVD. Participants were assigned to the\naddition of 5 mg or 15 mg of ertugli flozin\nor to placebo once daily to background\nstandard care. Study participants had amean age of 64.4 years and a... | [
0.052536021918058395,
0.035111941397190094,
-0.05949443206191063,
0.038852509111166,
-0.060937654227018356,
-0.02045644447207451,
0.029681921005249023,
0.1498386263847351,
0.0127190500497818,
-0.03900749981403351,
-0.04533698782324791,
0.05290701240301132,
-0.07441384345293045,
-0.03684182... |
tion of diabetes of 13 years at baseline and\nwere followed for a median of 3.0 years.VERTIS CV met the prespeci fied criteria\nfor noninferiority of ertugli flozin to pla-\ncebo with respect to the primary out-come of major adverse cardiovascularevents (11.9% in the pooled ertugli flozin | [
-0.03753989562392235,
0.024270296096801758,
-0.06566912680864334,
0.014517770148813725,
-0.03700628504157066,
0.037711068987846375,
-0.026925701647996902,
0.14697697758674622,
-0.02087012119591236,
-0.06276559829711914,
-0.014746122062206268,
-0.009240306913852692,
-0.06896569579839706,
-0... |
group and 11.9% in the placebo group;HR 0.97 [95% CI 0.85– 1.11]; P<0.001).\nErtugli flozin was not superior to placebo\nfor the key secondary outcomes of deathfrom cardiovascular causes or hospitali-zation for heart failure; death from car-\ndiovascular causes; or the composite of | [
0.016108565032482147,
0.011079864576458931,
-0.09480658918619156,
0.002930279355496168,
-0.0037198623176664114,
0.007141090463846922,
-0.016346927732229233,
0.17473989725112915,
0.04839007556438446,
-0.05610494688153267,
0.000560954213142395,
0.0361398346722126,
-0.010912997648119926,
0.02... |
diovascular causes; or the composite of\ndeath from renal causes, renal replacementtherapy, or doubling of the serum creati-nine level. The HR for a secondary outcome\nof hospitalization for heart failure (ertugli-\nflozin vs. placebo) was 0.70 [95% CI\n0.54– 0.90], consistent with findings from\nother SGLT2 inhibitor ca... | [
-0.018641691654920578,
0.04576056823134422,
0.02030188776552677,
0.02156076207756996,
-0.003913493826985359,
-0.08745361864566803,
-0.05747139826416969,
0.16915668547153473,
0.000026687674107961357,
-0.03293151408433914,
-0.03275199607014656,
-0.016836706548929214,
-0.028723353520035744,
0... |
other SGLT2 inhibitor cardiovascular out-comes trials.\nGLP-1 Receptor Agonist Trials\nThe Liraglutide Effect and Action inDiabetes: Evaluation of CardiovascularOutcome Results (LEADER) trial was a ran-domized, double-blind trial that assessed\nthe effect of liraglutide, a glucagon-like | [
-0.007007715757936239,
0.004666817374527454,
-0.08551054447889328,
0.01815474033355713,
0.015710894018411636,
0.025505539029836655,
-0.11236801743507385,
0.1112934798002243,
0.017005925998091698,
-0.038642480969429016,
0.030693279579281807,
0.04750726744532585,
-0.030957113951444626,
-0.01... |
the effect of liraglutide, a glucagon-like\npeptide 1 (GLP-1) receptor agonist, ver-sus placebo on cardiovascular outcomesin 9,340 people with type 2 diabetes at\nhigh risk for cardiovascular disease or\nwith cardiovascular disease (256). Studyparticipants had a mean age of 64 yearsand a mean duration of diabetes of | [
0.006626082118600607,
-0.014091036282479763,
-0.09671247750520706,
0.011722938157618046,
-0.038911812007427216,
0.031730495393276215,
-0.030294079333543777,
0.1028287336230278,
0.02918989211320877,
-0.04397692158818245,
0.007798365317285061,
0.07078774273395538,
-0.038181282579898834,
-0.0... |
nearly 13 years. Over 80% of study par-\nticipants had established cardiovasculardisease. After a median follow-up of3.8 years, LEADER showed that the pri-mary composite outcome (MI, stroke, orcardiovascular death) occurred in fewerparticipants in the treatment group (13.0%)\nthan in the placebo group (14.9%) (HR 0.87 | [
0.008919917978346348,
0.016217617318034172,
-0.008795519359409809,
0.03968140855431557,
-0.037186410278081894,
0.007119201123714447,
-0.13391053676605225,
0.16000783443450928,
-0.009481466375291348,
-0.0066179814748466015,
0.08643343299627304,
0.08001580089330673,
-0.006017315201461315,
-0... |
than in the placebo group (14.9%) (HR 0.87\n[95% CI 0.78 –0.97]; P<0.001 for nonin-\nferiority; P= 0.01 for superiority). Deaths\nfrom cardiovascular causes were signi fi-\ncantly reduced in the liraglutide group(4.7%) compared with the placebo group(6.0%) (HR 0.78 [95% CI 0.66 –0.93]; P=\n0.007) (256).\nResults from a ... | [
0.0902799442410469,
0.004209402482956648,
-0.06321703642606735,
0.004625684581696987,
0.0029356377199292183,
-0.024576272815465927,
-0.1039695143699646,
0.12877386808395386,
0.02223934605717659,
-0.04378674179315567,
-0.0024184526409953833,
0.014536449685692787,
-0.02206290327012539,
-0.03... |
0.007) (256).\nResults from a moderate-sized trial\nof another GLP-1 receptor agonist, sema-glutide, were consistent with the LEADERtrial (257). Semaglutide is a once-weeklyGLP-1 receptor agonist approved by the\nFDA for the treatment of type 2 diabetes. | [
0.03143933415412903,
0.020250840112566948,
-0.05813559889793396,
0.04680885002017021,
-0.08745590597391129,
-0.00231726560741663,
0.004129327833652496,
0.11762059479951859,
-0.0011654365807771683,
-0.03858715668320656,
-0.027368508279323578,
-0.00028046630905009806,
-0.06142314150929451,
0... |
FDA for the treatment of type 2 diabetes.\nThe Trial to Evaluate Cardiovascular andOther Long-term Outcomes With Semaglu-tide in Subjects With Type 2 Diabetes(SUSTAIN-6) was the initial randomized\ntrial powered to test noninferiority of sem- | [
-0.025799736380577087,
-0.00035987404407933354,
-0.02215707302093506,
0.049946706742048264,
-0.03712612763047218,
-0.0013174443738535047,
-0.053175315260887146,
0.10366716235876083,
-0.048930808901786804,
-0.02776159904897213,
-0.039763666689395905,
0.03256771340966225,
-0.04822347313165665,... |
trial powered to test noninferiority of sem-\naglutide for the purpose of regulatory ap-proval (257). In this study, 3,297 peoplewith type 2 diabetes were randomized to\nreceive once-weekly semaglutide (0.5 mg\nor 1.0 mg) or placebo for 2 years. The pri-mary outcome (the first occurrence of car-\ndiovascular death, nonf... | [
0.036558665335178375,
-0.03373608738183975,
-0.045317940413951874,
0.016132164746522903,
-0.04627455025911331,
-0.0077929310500621796,
0.04888995736837387,
0.16207602620124817,
0.021626902744174004,
0.005579074844717979,
0.03061564266681671,
0.02838549204170704,
0.036062102764844894,
-0.06... |
diovascular death, nonfatal MI, or nonfatal\nstroke) occurred in 108 individuals (6.6%)\nin the semaglutide group vs. 146 individu-als (8.9%) in the placebo group (HR 0.74[95% CI 0.58– 0.95]; P<0.001). More indi-\nviduals discontinued treatment in the sem-\naglutide group because of adverse events, | [
0.046406302601099014,
-0.026663608849048615,
-0.006754204165190458,
-0.001701115514151752,
-0.08973375707864761,
-0.08715899288654327,
-0.047550082206726074,
0.1534499228000641,
0.007261719089001417,
-0.017019696533679962,
0.0055552637204527855,
-0.005924577359110117,
0.006169252563267946,
... |
aglutide group because of adverse events,\nmainly gastrointestinal. The cardiovasculareffects of the oral formulation of semaglu-tide compared with placebo have been\nassessed in Peptide Innovation for Early\nDiabetes Treatment (PIONEER) 6, a preap-proval trial designed to rule out an unac-ceptable increase in cardiova... | [
-0.04012952372431755,
-0.0241396501660347,
-0.06079237908124924,
0.010836292989552021,
-0.0057061887346208096,
0.02796764299273491,
-0.008144901134073734,
0.14337626099586487,
0.022113505750894547,
-0.03286704793572426,
0.008362499065697193,
0.040731415152549744,
-0.08540185540914536,
-0.0... |
(257). In this trial of 3,183 people with\ntype 2 diabetes and high cardiovascularrisk followed for a median of 15.9 months,oral semaglutide was noninferior to pla-cebo for the primary composite outcome\nof cardiovascular death, nonfatal MI, or\nnonfatal stroke (HR 0.79 [95% CI 0.57 –\n1.11]; P<0.001 for noninferiority... | [
0.004892376251518726,
-0.007682568393647671,
-0.08427160978317261,
-0.008655890822410583,
-0.10756278783082962,
0.0022741956636309624,
-0.036506157368421555,
0.1558094620704651,
0.04841800034046173,
-0.024340976029634476,
-0.03516741469502449,
-0.026342270895838737,
-0.014720702543854713,
... |
1.11]; P<0.001 for noninferiority) (257).\nThe cardiovascular effects of this formula-\ntion of semaglutide will be further tested\nin a large, longer-term outcomes trial.\nThe Harmony Outcomes trial random-\nized 9,463 people with type 2 diabetesand cardiovascular disease to once-weekly\nsubcutaneous albiglutide or ma... | [
-0.003955117892473936,
0.037405990064144135,
0.006248992867767811,
0.021967481821775436,
-0.08304324001073837,
0.004137223120778799,
-0.05400375649333,
0.14505013823509216,
0.007711377460509539,
-0.051526471972465515,
0.003080193419009447,
-0.010636067017912865,
0.015607215464115143,
-0.05... |
subcutaneous albiglutide or matching pla-\ncebo, in addition to their standard care(258). Over a median duration of 1.6 years,\nthe GLP-1 receptor agonist reduced the | [
-0.03870151937007904,
0.007143834605813026,
-0.06546235829591751,
0.005324963945895433,
-0.12672242522239685,
-0.022560877725481987,
-0.01594235934317112,
0.12628187239170074,
0.014226814731955528,
-0.05388193577528,
0.06531170010566711,
-0.034443967044353485,
-0.043964650481939316,
0.0452... |
the GLP-1 receptor agonist reduced the\nrisk of cardiovascular death, MI, or stroketo an incidence rate of 4.6 events per100 person-years in the albiglutide groupvs. 5.9 events in the placebo group (HR0.78, P= 0.0006 for superiority) (258).\nThis agent is not currently available forclinical use.\nThe Researching Cardio... | [
0.023213420063257217,
0.008720689453184605,
-0.0711272805929184,
0.02751947194337845,
-0.082423135638237,
0.014585842378437519,
-0.05859104171395302,
0.0665556788444519,
0.05234025791287422,
-0.02800564281642437,
0.0376763679087162,
-0.012461851350963116,
-0.08055397123098373,
0.0135788973... |
The Researching Cardiovascular Events\nWith a Weekly Incretin in Diabetes(REWIND) trial was a randomized, double-blind, placebo-controlled trial that assessedthe effect of the once-weekly GLP-1 recep-tor agonist dulaglutide versus placebo on\nmajor adverse cardiovascular events in\n/C249,990 people with type 2 diabetes... | [
-0.06831975281238556,
0.052963532507419586,
-0.0232243612408638,
-0.012547153048217297,
-0.035207025706768036,
0.020916327834129333,
-0.04482003673911095,
0.06106947362422943,
0.028821861371397972,
-0.032433975487947464,
-0.04398065060377121,
0.05393500626087189,
-0.11830130219459534,
-0.0... |
/C249,990 people with type 2 diabetes at\nrisk for cardiovascular events or with a his-tory of cardiovascular disease (259). Studyparticipants had a mean age of 66 yearsand a mean duration of diabetes of\n/C2410 years. Approximately 32% of partici-\npants had history of atherosclerotic cardio- | [
0.07257073372602463,
0.020906217396259308,
-0.06113139167428017,
0.06984181702136993,
-0.08012152463197708,
0.006050270050764084,
-0.029298799112439156,
0.10582982748746872,
-0.05936826765537262,
-0.056939348578453064,
-0.031973861157894135,
-0.0304926335811615,
-0.058188360184431076,
-0.0... |
pants had history of atherosclerotic cardio-\nvascular events at baseline. After a medianfollow-up of 5.4 years, the primary com-posite outcome of nonfatal MI, nonfatalstroke, or death from cardiovascular\ncauses occurred in 12.0% and 13.4% of | [
0.008950413204729557,
0.03078562207520008,
0.0035402693320065737,
0.06411544233560562,
-0.004867058712989092,
-0.01940813474357128,
-0.015537084080278873,
0.10488901287317276,
-0.029973231256008148,
-0.01623760163784027,
0.05146421864628792,
0.06114748492836952,
0.021753361448645592,
0.021... |
causes occurred in 12.0% and 13.4% of\nparticipants in the dulaglutide and pla-cebo treatment groups, respectively(HR 0.88 [95% CI 0.79 –0.99]; P= 0.026).\nThese findings equated to incidence rates\nof 2.4 and 2.7 events per 100 person-years,respectively. The results were consistent\nacross the subgroups of individuals ... | [
0.02822870947420597,
0.019083602353930473,
0.02421582117676735,
-0.0176839642226696,
-0.002057065023109317,
0.008335155434906483,
-0.0009196478058584034,
0.16424956917762756,
0.012311997823417187,
0.029609382152557373,
0.10200941562652588,
-0.02907777763903141,
-0.018476318567991257,
0.015... |
across the subgroups of individuals with\nand without history of CV events. All-causemortality did not differ between groups(P= 0.067).\nThe Evaluation of Lixisenatide in\nAcute Coronary Syndrome (ELIXA) trial\nstudied the once-daily GLP-1 receptor\nagonist lixisenatide on cardiovascular | [
0.018566474318504333,
-0.0019984787795692682,
-0.014131585136055946,
0.017270172014832497,
0.030657269060611725,
-0.014418047852814198,
-0.002460189862176776,
0.0981120839715004,
-0.010186884552240372,
-0.029842443764209747,
0.06071385741233826,
0.000759572722017765,
-0.019563322886824608,
... |
agonist lixisenatide on cardiovascular\noutcomes in people with type 2 diabe-tes who had had a recent acute coro-nary event (261). A total of 6,068people with type 2 diabetes with a re-cent hospitalization for MI or unstableangina within the previous 180 days\nwere randomized to receive lixisena- | [
0.054237574338912964,
-0.012523732148110867,
-0.06950455158948898,
0.007878012955188751,
-0.04129097983241081,
-0.04582604765892029,
0.023033710196614265,
0.07291609048843384,
-0.018765009939670563,
-0.0032963547855615616,
0.0009518807055428624,
0.02132124826312065,
-0.010606523603200912,
... |
were randomized to receive lixisena-\ntide or placebo in addition to standardcare and were followed for a medianof/C242.1 years. The primary outcome of\ncardiovascular death, MI, stroke, orhospitalization for unstable angina oc-\ncurred in 406 individuals (13.4%) in | [
0.02611134946346283,
-0.027145059779286385,
-0.022948842495679855,
0.012095070444047451,
0.0014261144679039717,
-0.05069641396403313,
-0.0649186447262764,
0.13703517615795135,
0.018978236243128777,
-0.006253859493881464,
-0.018124911934137344,
0.04048158973455429,
0.004696935415267944,
-0.... |
curred in 406 individuals (13.4%) in\nthe lixisenatide group vs. 399 (13.2%)in the placebo group (HR 1.2 [95% CI0.89– 1.17]), which demonstrated the\nnoninferiority of lixisenatide to placeboS204 Cardiovascular Disease and Risk Management Diabetes Care Volume 47, Supplement 1, January 2024\n©AmericanDiabetesAssociation | [
0.06062674522399902,
-0.07138681411743164,
-0.08725452423095703,
0.04235711321234703,
-0.013874373398721218,
-0.036895785480737686,
0.025476569309830666,
0.112032450735569,
0.005537381395697594,
-0.07350683212280273,
-0.0022380128502845764,
0.02500765770673752,
0.027589334174990654,
-0.025... |
(P<0.001) but did not show superiority\n(P= 0.81).\nThe Exenatide Study of Cardiovascu-\nlar Event Lowering (EXSCEL) trial also\nreported results with the once-weekly\nGLP-1 receptor agonist extended-release | [
0.09159667044878006,
-0.002287383424118161,
-0.045895565301179886,
0.06461408734321594,
-0.006799571681767702,
-0.03559345006942749,
-0.06722408533096313,
0.1804920732975006,
0.044856853783130646,
-0.008760025724768639,
0.03241214156150818,
0.06127333268523216,
-0.023450467735528946,
0.047... |
GLP-1 receptor agonist extended-release\nexenatide and found that major adversecardiovascular events were numericallylower with use of extended-release exe-natide compared with placebo, although\nthis difference was not statistically signif-\nicant (261). A total of 14,752 peoplewith type 2 diabetes (of whom 10,782[73.... | [
0.025756636634469032,
0.0009773630881682038,
-0.06384928524494171,
0.044919222593307495,
-0.04551062360405922,
-0.030411778017878532,
0.009058244526386261,
0.11268390715122223,
0.022747354581952095,
-0.02265152707695961,
0.03567291051149368,
0.05420570448040962,
-0.10026532411575317,
0.013... |
disease) were randomized to receive\nextended-release exenatide 2 mg orplacebo and followed for a median of3.2 years. The primary end point of\ncardiovascular death, MI, or stroke oc-\ncurred in 839 individuals (11.4%; 3.7events per 100 person-years) in the ex-enatide group and in 905 individuals(12.2%; 4.0 events per ... | [
0.04027881100773811,
-0.028405318036675453,
-0.02944805473089218,
-0.006193317007273436,
0.00278598815202713,
-0.030304506421089172,
0.018941817805171013,
0.13370613753795624,
0.062142569571733475,
0.08583031594753265,
0.08284955471754074,
0.0077472347766160965,
-0.00784862507134676,
-0.04... |
years) in the placebo group (HR 0.91\n[95% CI 0.83 –1.00]; P<0.001 for non-\ninferiority), but exenatide was not supe-rior to placebo with respect to the\nprimary end point ( P= 0.06 for superi-\nority). However, all-cause mortality was\nlower in the exenatide group (HR 0.86[95% CI 0.77 –0.97]). The incidence of | [
0.04808354005217552,
-0.019735125824809074,
-0.09228264540433884,
0.0035888743586838245,
0.014988872222602367,
-0.0344594344496727,
-0.02053411304950714,
0.19316910207271576,
0.023145632818341255,
0.03425741568207741,
0.0707164779305458,
0.03263063728809357,
0.002165622776374221,
0.0076490... |
acute pancreatitis, pancreatic cancer,medullary thyroid carcinoma, and seri-ous adverse events did not differ signi fi-\ncantly between the two groups.\nIn summary, there are now numerous\nlarge randomized controlled trials re-porting statistically signi ficant reduc- | [
0.033153630793094635,
-0.03146027773618698,
-0.00261511467397213,
-0.04173840209841728,
-0.011004691012203693,
0.00301665673032403,
-0.02421693503856659,
0.09763967990875244,
0.03616628795862198,
-0.04894726723432541,
0.03831987828016281,
0.0512925423681736,
-0.02725711278617382,
-0.002739... |
tions in cardiovascular events for threeof the FDA-approved SGLT2 inhibitors(empagli flozin, canagli flozin, and dapa-\ngliflozin, with lesser bene fits seen with\nertugli flozin) and four FDA-approved\nGLP-1 receptor agonists (liraglutide, al-biglutide [although that agent was re-\nmoved from the market for business | [
-0.09166094660758972,
-0.03761989623308182,
-0.09780480712652206,
-0.0017277401639148593,
0.00905598048120737,
0.04228191822767258,
-0.053023505955934525,
0.07190912216901779,
0.0014461181126534939,
-0.051099054515361786,
0.05318817123770714,
-0.007731366436928511,
-0.0687577947974205,
0.0... |
moved from the market for business\nreasons], semaglutide [lower risk ofcardiovascular events in a moderate-sized clinical trial but one not powered\nas a cardiovascular outcomes trial],\nand dulaglutide). Meta-analyses of thetrials reported to date suggest thatGLP-1 receptor agonists and SGLT2 in-hibitors reduce risk ... | [
-0.006608900148421526,
0.04377102106809616,
-0.045629628002643585,
0.03662747144699097,
0.011985820718109608,
-0.022008901461958885,
-0.06310275197029114,
0.11003424227237701,
0.03796198219060898,
-0.08864407986402512,
-0.060576289892196655,
0.028443418443202972,
-0.0026586181484162807,
-0... |
major adverse cardiovascular events to a\ncomparable degree in people with type 2diabetes and established ASCVD (262,263).SGLT2 inhibitors also reduce risk of heart\nfailure hospitalization and progression of | [
-0.016750382259488106,
0.004238730296492577,
-0.056091390550136566,
0.04182763025164604,
-0.010343380272388458,
0.021251771599054337,
-0.09167665988206863,
0.08780241757631302,
-0.02495310828089714,
-0.003888614010065794,
0.019030917435884476,
0.051575079560279846,
-0.06343665719032288,
-0... |
failure hospitalization and progression of\nkidney disease in people with establishedASCVD, multiple risk factors for ASCVD, oralbuminuric kidney disease (264,265). Inpeople with type 2 diabetes and estab-\nlished ASCVD, multiple ASCVD risk factors,\nor diabetic kidney disease, an SGLT2 in-hibitor with demonstrated car... | [
-0.023662935942411423,
-0.012293649837374687,
-0.0727660059928894,
0.005608800798654556,
-0.08868922293186188,
-0.02054198831319809,
-0.013969996012747288,
0.08102890104055405,
0.018165456131100655,
-0.05833970382809639,
-0.028917191550135612,
0.0030255140736699104,
0.00971776619553566,
-0... |
lar bene fit is recommended to reduce\nthe risk of major adverse cardiovascular\nevents and/or heart failure hospitaliza-\ntion. In people with type 2 diabetes and\nestablished ASCVD or multiple risk factorsfor ASCVD, a GLP-1 receptor agonist with\ndemonstrated cardiovascular bene fiti s | [
-0.03271065652370453,
-0.032812219113111496,
-0.08572731912136078,
-0.01515916083008051,
-0.03129580616950989,
0.05578062683343887,
0.027966095134615898,
0.11408500373363495,
0.008199842646718025,
-0.027194794267416,
0.02422945573925972,
0.019587108865380287,
-0.08102026581764221,
0.015390... |
demonstrated cardiovascular bene fiti s\nrecommended to reduce the risk of ma-jor adverse cardiovascular events. For\nmany individuals, use of either an SGLT2i n h i b i t o ro raG L P - 1r e c e p t o ra g o n i s tt o\nreduce cardiovascular risk is appropriate.\nEmerging data suggest that use of bothclasses of drugs w... | [
-0.04288569465279579,
0.01448750775307417,
-0.013789433054625988,
-0.022936996072530746,
-0.026290342211723328,
0.041345372796058655,
-0.046388790011405945,
0.13425830006599426,
-0.03171406686306,
-0.03383979573845863,
0.017880210652947426,
0.015203476883471012,
0.0006912064854986966,
-0.0... |
cardiovascular and kidney outcomes ben-\nefit; thus, combination therapy with an\nSGLT2 inhibitor and a GLP-1 receptor ag-\nonist may be considered to provide the\ncomplementary outcomes bene fits asso-\nciated with these classes of medication.\nEvidence to support such an approach\nincludes findings from AMPLITUDE-O | [
-0.05834474787116051,
-0.01483539305627346,
0.0052838679403066635,
-0.04779203608632088,
-0.10267898440361023,
-0.018713677302002907,
0.02813143841922283,
0.13431605696678162,
0.01904267631471157,
-0.03624553605914116,
-0.004035616293549538,
0.0461474247276783,
-0.036796461790800095,
0.028... |
includes findings from AMPLITUDE-O\n(Effect of Efpeglenatide on Cardiovascular\nOutcomes), an outcomes trial of people\nwith type 2 diabetes and either cardio-\nvascular or kidney disease plus at least\none other risk factor randomized to theinvestigational GLP-1 receptor agonist ef-\npeglenatide or placebo (266). Rando... | [
0.047772862017154694,
-0.036753226071596146,
-0.03534424304962158,
-0.00811074674129486,
-0.009773851372301579,
-0.025193439796566963,
0.018260164186358452,
0.11094193905591965,
0.057628240436315536,
0.012568602338433266,
0.025319557636976242,
0.016793083399534225,
-0.09127470850944519,
-0... |
peglenatide or placebo (266). Randomiza-\ntion was strati fied by current or potential\nuse of SGLT2 inhibitor therapy, a class ul-timately used by >15% of the trial par-\nticipants. Over a median follow-up of 1.8\nyears, efpeglenatide therapy reduced the\nrisk of incident major adverse cardiovas- | [
-0.007489839103072882,
0.001969976117834449,
-0.09284502267837524,
0.012100648134946823,
-0.020134171470999718,
-0.062436074018478394,
0.052743613719940186,
0.14295604825019836,
0.05005250871181488,
-0.010786455124616623,
0.01555502787232399,
0.05366864055395126,
-0.05070372670888901,
-0.0... |
risk of incident major adverse cardiovas-\ncular events by 27% and of a compositerenal outcome event by 32%. Importantly,\nthe effects of efpeglenatide did not vary\nby use of SGLT2 inhibitors, suggesting that\nthe bene ficial effects of the GLP-1 recep-\ntor agonist were independent of those\nprovided by SGLT2 inhibito... | [
0.044812604784965515,
-0.020302897319197655,
-0.05220259726047516,
0.03249175846576691,
0.003607427468523383,
0.010302715934813023,
-0.044318560510873795,
0.17745807766914368,
0.0277691762894392,
-0.004166837316006422,
0.046755269169807434,
0.022541619837284088,
-0.034691400825977325,
-0.0... |
provided by SGLT2 inhibitor therapy (267).\nEfpeglenatide is currently not approved by\nthe FDA for use in the U.S.\nPrevention and Treatment of Heart\nFailure\nPrevention of Symptomatic Heart Failure\nACE Inhibitors/ARBs and b-Blockers. Early\nprimary prevention strategies and treat-\nment of associated risk factors r... | [
-0.028033792972564697,
-0.04923897236585617,
-0.08954885601997375,
-0.027567990124225616,
0.03816551715135574,
0.003864889731630683,
-0.03915459290146828,
0.12085124850273132,
-0.00947326049208641,
-0.0023509312886744738,
0.010410823859274387,
0.02736133523285389,
-0.0423436239361763,
-0.0... |
ment of associated risk factors reduce in-\ncident, symptomatic heart failure andshould include lifestyle intervention with\ndiet, physical activity, weight control, andsmoking cessation (268 –271). The vast\nmajority of incident heart failure is pre- | [
0.06973318010568619,
0.05149821564555168,
0.00032785555231384933,
0.03118041343986988,
0.04694518819451332,
0.04382741451263428,
-0.04271713271737099,
0.061757929623126984,
-0.08374543488025665,
-0.0691385567188263,
0.045928362756967545,
-0.01443038135766983,
0.03719178959727287,
-0.037346... |
majority of incident heart failure is pre-\nceded by hypertension; up to 91% of allnew heart failure development in theFramingham cohort occurred in people\nwith a previous diagnosis of hypertension\n(272). Therefore, management of hyper-tension constitutes a key goal in peoplewith diabetes and stage A or B heart fail- | [
0.017863543704152107,
0.03163846209645271,
-0.04017956927418709,
0.01883533038198948,
-0.04531208798289299,
0.02799808233976364,
-0.0030944121535867453,
0.018809467554092407,
-0.07743380218744278,
-0.05559355393052101,
-0.012790498323738575,
-0.00014494908100459725,
-0.01807992160320282,
-... |
ure. For example, in the UKPDS trial, in-\ntensive blood pressure control in peoplewith type 2 diabetes reduced the risk forheart failure by 56% (273). Similarly, inthe SPRINT trial, intensive treatment of\nhypertension decreased the risk for de-\nvelopment of incident heart failure by36% (274). As discussed in the\nHY... | [
-0.0163522157818079,
0.06928239017724991,
-0.011046894825994968,
0.024908000603318214,
-0.00929684191942215,
0.024747343733906746,
-0.024819176644086838,
0.12906357645988464,
0.013331631198525429,
0.0040501379407942295,
-0.020718418061733246,
0.0682254284620285,
-0.02263285033404827,
-0.01... |
HYPERTEN-\nSION/BLOOD PRESSURE CONTROL section above,\nuse of ACE inhibitors or ARBs is the pre-ferred treatment strategy for manage-ment of hypertension in people withdiabetes, particularly in the presence ofalbuminuria or coronary artery disease.\nPeople with diabetes and stage B heart | [
-0.05223337188363075,
-0.03554331138730049,
-0.1505790650844574,
0.03435463830828667,
-0.02492750808596611,
0.004074350465089083,
0.11210481822490692,
0.05225572735071182,
-0.029075250029563904,
-0.02311038039624691,
0.029258111491799355,
0.05165128782391548,
-0.05822274833917618,
-0.04847... |
People with diabetes and stage B heart\nfailure who remain asymptomatic buthave evidence of structural heart disease,including history of MI, acute coronary\nsyndrome, or left ventricular ejection frac-\ntion (LVEF) #40%, should be treated\nwith ACE inhibitors/ARBs plus b-blockers\naccording to current treatment guidel... | [
-0.0056047504767775536,
0.01131278183311224,
-0.06477820873260498,
0.009789335541427135,
-0.020875291898846626,
0.029298260807991028,
-0.040518663823604584,
0.03763526678085327,
-0.025371216237545013,
-0.02150428667664528,
-0.03086499683558941,
0.01084605697542429,
-0.09110662341117859,
0.... |
according to current treatment guidelines\n(210). In the landmark Studies of Left\nVentricular Dysfunction (SOLVD) study, inwhich 15% of people had diabetes, treat-ment with enalapril reduced incidentheart failure in people with asymptomatic\nleft ventricular dysfunction by 20% (275). | [
-0.004446947015821934,
0.02968202345073223,
-0.0225908812135458,
0.05145396292209625,
-0.012920508161187172,
0.016088640317320824,
-0.04635728895664215,
0.1099749356508255,
-0.01961975172162056,
-0.05470220744609833,
0.03134714812040329,
0.03437340259552002,
-0.07335345447063446,
0.0048098... |
left ventricular dysfunction by 20% (275).\nIn the Survival and Ventricular Enlarge-ment (SAVE) study, which enrolled asymp-tomatic people with reduced LVEF after\nMI, including 23% people with diabetes, | [
0.06627584248781204,
0.010742026381194592,
-0.05781104788184166,
0.03329779580235481,
0.07381275296211243,
0.028900541365146637,
-0.09182123094797134,
0.09906536340713501,
-0.04090731590986252,
-0.04578020051121712,
0.022379515692591667,
0.046420931816101074,
-0.02923305332660675,
0.001042... |
MI, including 23% people with diabetes,\ntreatment with captopril reduced the de-velopment of heart failure by 37% (276).Subsequent retrospective analyses fromboth trials revealed that concomitant use\nofb-blockers was associated with de-\ncreased risk of progression to symptom- | [
-0.03032081387937069,
-0.03653740882873535,
-0.04824196174740791,
0.015287947840988636,
-0.023634590208530426,
-0.013332119211554527,
0.020803699269890785,
0.1506333202123642,
0.006338099017739296,
-0.057644475251436234,
0.002966525498777628,
0.055057283490896225,
-0.03966875746846199,
0.0... |
creased risk of progression to symptom-\natic heart failure (277,278). The CarvedilolPost-Infarct Survival Control in Left Ven-\ntricular Dysfunction (CAPRICORN) study\nrandomized people with a history of MIand reduced LVEF to treatment with car-vedilol (279). Approximately half of thestudy participants were asymptomat... | [
0.016611957922577858,
-0.03720090538263321,
0.009509961120784283,
0.045913733541965485,
0.08649943768978119,
0.039505485445261,
-0.10955485701560974,
0.1561201512813568,
-0.024081934243440628,
-0.02027365192770958,
0.003130311379209161,
-0.010676379315555096,
-0.03301941603422165,
-0.01513... |
and 23% of study participants had a his-\ntory of diabetes. Treatment with carvedi-lol reduced mortality by 23%, and therewas a 14% risk reduction for heart failure\nhospitalization. Finally, in the Reversal of\nVentricular Remodeling With Toprol-XLdiabetesjournals.org/care Cardiovascular Disease and Risk Management S2... | [
0.023304490372538567,
0.042215824127197266,
-0.010211988352239132,
0.03965316340327263,
-0.059925977140665054,
0.012938974425196648,
-0.052435994148254395,
0.09791449457406998,
-0.07804704457521439,
-0.007006141357123852,
0.005731659941375256,
0.04382290691137314,
-0.018986361101269722,
-0... |
(REVERT) trial, in which 45% of the peo-\nple enrolled had diabetes, metoprololimproved adverse cardiac remodeling inasymptomatic individuals with an LVEF<40% and mild left ventricular dilatation\n(280).\nSGLT Inhibitors. As reviewed in detail in | [
-0.003917639143764973,
0.030987348407506943,
-0.014755592681467533,
-0.003538793418556452,
0.02575448527932167,
-0.010217905044555664,
-0.06491585820913315,
0.13094615936279297,
0.023943981155753136,
0.016743309795856476,
0.025391709059476852,
0.06730733811855316,
-0.07741662114858627,
-0.... |
(280).\nSGLT Inhibitors. As reviewed in detail in\nthe following section, SGLT2 inhibitorsconstitute a key treatment approach toreduce cardiovascular disease and heartfailure outcomes in people with diabe-tes. People with type 2 diabetes and\nincreased cardiovascular risk or estab- | [
-0.02575281634926796,
0.01655956171452999,
-0.0890878438949585,
-0.0024517730344086885,
-0.036804549396038055,
0.0008455797797068954,
-0.022914351895451546,
0.1653246134519577,
-0.0020479094237089157,
-0.028156405314803123,
0.023921962827444077,
0.017721066251397133,
-0.04621383547782898,
... |
increased cardiovascular risk or estab-\nlished cardiovascular disease should betreated with an SGLT2 inhibitor to pre-vent the development of incident heartfailure. This includes people with type 2diabetes and asymptomatic stage B heart\nfailure. In the EMPA-REG OUTCOME trial, | [
-0.013062315061688423,
0.004805448465049267,
-0.06158626452088356,
0.025055987760424614,
0.009197946637868881,
0.0009984263451769948,
-0.09011876583099365,
0.07346153259277344,
-0.010085508227348328,
-0.015994200482964516,
0.06608392298221588,
0.005389997735619545,
-0.03866181895136833,
-0... |
failure. In the EMPA-REG OUTCOME trial,\nonly 10% of study participants had aprior history of heart failure, and treat-ment with empagli flozin reduced the rel-\native risk for hospitalization from heartfailure by 35% (11). In the CANVAS Pro-gram, hospitalization from heart failure\nwas reduced by 33% in people allocate... | [
0.009875519201159477,
0.06551429629325867,
-0.006526358425617218,
-0.015951426699757576,
0.01631229557096958,
-0.01614762842655182,
-0.021190734580159187,
0.16790126264095306,
-0.03361821174621582,
-0.0023262007161974907,
0.04464990273118019,
0.015227536670863628,
0.015110949985682964,
0.0... |
was reduced by 33% in people allocated\nto canagli flozin, and only 14% of individu-\nals enrolled had a prior history of heartfailure (12). In the DAPA-HF study, only10% of study participants had a priorhistory of heart failure, and dapagli flozin | [
-0.002186858095228672,
0.087223581969738,
-0.07122854888439178,
0.038174666464328766,
-0.008840375579893589,
-0.011347586289048195,
-0.06403395533561707,
0.07121173292398453,
-0.08325172960758209,
-0.041768208146095276,
0.04999760538339615,
0.013996230438351631,
-0.04721476137638092,
0.012... |
reduced cardiovascular mortality andhospitalization for heart failure by 17%,which was consistent across multiplestudy subgroups regardless of a prior his-tory of heart failure (249). Finally, in theEffect of Sotagli flozin on Cardiovascular\nand Renal Events in Participants With\nType 2 Diabetes and Moderate Renal | [
0.0749947801232338,
0.05374603345990181,
-0.01774722710251808,
-0.0014480670215561986,
0.004735283553600311,
-0.0006964141502976418,
-0.02115672640502453,
0.06309432536363602,
-0.018667718395590782,
-0.0861978679895401,
-0.04161912947893143,
0.049243856221437454,
-0.05421790853142738,
0.03... |
Type 2 Diabetes and Moderate Renal\nImpairment Who Are at CardiovascularRisk (SCORED) trial, randomization to theSGLT1/2 inhibitor sotagli flozin reduced the\nprimary outcome of death from cardiovas-cular causes, hospitalizations for heart fail-\nure, and urgent visits for heart failure in | [
0.03503268212080002,
0.04527509585022926,
-0.0497761070728302,
0.03358205407857895,
0.01591186411678791,
-0.02913668006658554,
-0.028673522174358368,
0.11857841908931732,
-0.00012570437684189528,
-0.05805562809109688,
-0.04330642148852348,
0.05581216886639595,
-0.08650768548250198,
0.00931... |
ure, and urgent visits for heart failure in\npeople with type 2 diabetes, CKD, and riskfor cardiovascular disease (281). Therefore,SGLT inhibitor treatment is recommendedin asymptomatic people with type 2 dia-betes at risk or with established cardiovas-\ncular disease to prevent incident heart\nfailure and hospitalizat... | [
-0.04233720153570175,
0.002052015159279108,
-0.0557289645075798,
-0.0046190787106752396,
-0.036908868700265884,
0.00011718922905856743,
-0.025376595556735992,
0.12307527661323547,
-0.026749256998300552,
-0.05861399695277214,
0.0072868638671934605,
0.055364202708005905,
-0.039750080555677414,... |
failure and hospitalization from heartfailure.\nFinerenone. Finerenone is a nonsteroidal\nMRA and has recently been studied in\npeople with diabetes and diabetic kid-\nney disease, including the Finerenonein Reducing Kidney Failure and DiseaseProgression in Diabetic Kidney Disease\n(FIDELIO-DKD) and the Ef ficacy and | [
-0.02954365871846676,
-0.02219497598707676,
-0.0008081818232312799,
-0.003199623432010412,
-0.012223482131958008,
-0.04947715252637863,
0.01276006642729044,
0.14537474513053894,
-0.022210417315363884,
-0.09281916171312332,
-0.004043518099933863,
0.02535492368042469,
-0.1059020608663559,
0.... |
(FIDELIO-DKD) and the Ef ficacy and\nSafety of Finerenone in Subjects With\nType 2 Diabetes Mellitus and the Clini-cal Diagnosis of Diabetic Kidney Disease(FIGARO-DKD) studies. In FIDELIO-DKD,finerenone was compared with placebo\nfor the primary outcome of kidney fail-ure, a sustained decrease of at least40% in the eGFR ... | [
-0.02330409176647663,
0.009966697543859482,
-0.0070096696726977825,
-0.03675094619393349,
-0.032122571021318436,
-0.09875350445508957,
0.026944542303681374,
0.1510293185710907,
0.0515875443816185,
-0.0422380156815052,
-0.07381878048181534,
0.011207802221179008,
-0.05815521255135536,
-0.021... |
death from renal causes in people with\ntype 2 diabetes and diabetic kidneydisease (282). A prespeci fied secondary\noutcome was death from cardio-vascular causes, nonfatal MI, nonfatalstroke, or hospitalization for heart fail-ure, which was reduced by 13% in thefinerenone group. The incidence of | [
0.027422137558460236,
0.023754626512527466,
0.02574262209236622,
-0.032073572278022766,
-0.07725498080253601,
-0.028187565505504608,
0.029490098357200623,
0.09964945912361145,
0.02379189431667328,
0.025931665673851967,
-0.041886065155267715,
0.029711440205574036,
-0.005237797275185585,
-0.... |
heart failure hospitalization occurredless in the finerenone-treated group,\nand only 7.7% of study participantshad a prior history of heart failure. Inthe FIGARO-DKD trial, finerenone re-\nduced the primary outcome of deathfrom cardiovascular causes, nonfatalMI, nonfatal stroke, or hospitalizationfor heart failure (HR 0... | [
0.005213634576648474,
0.03432660922408104,
-0.03763109818100929,
-0.03464130312204361,
-0.0036100251600146294,
-0.03696577996015549,
-0.09795348346233368,
0.13166190683841705,
0.0245688334107399,
-0.016703303903341293,
-0.03023071214556694,
-0.006469862535595894,
-0.056372031569480896,
-0.... |
0.76–0.98]; P= 0.03) in people with\ntype 2 diabetes and diabetic kidney\ndisease (240). Only 7.8% of all partici-pants had a prior history of heartfailure, and the incidence of hospitali-zation for heart failure was reduced inthefinerenone-allocated treatment arm\n(HR 0.71 [95% CI 0.56– 0.90]). Owing to\nthese observat... | [
0.04447979852557182,
0.06415155529975891,
-0.0057115438394248486,
0.013991223648190498,
-0.04832519218325615,
-0.06929167360067368,
0.07778381556272507,
0.13667446374893188,
-0.009209983982145786,
-0.05531468987464905,
-0.01931108348071575,
0.054827671498060226,
-0.014499465003609657,
0.02... |
these observations, treatment with fi-\nnerenone is recommended in peoplewith type 2 diabetes and diabetic kidneydisease to reduce the risk of progressionfrom stage A heart failure to symptom-atic incident heart failure.\nTreatment of Symptomatic Heart\nFailure\nIn general, current guideline-directed | [
-0.021103395149111748,
-0.009031753055751324,
-0.0436747781932354,
-0.031130170449614525,
-0.005715434905141592,
-0.006663904991000891,
-0.02441304549574852,
0.13945183157920837,
0.013007663190364838,
-0.06682242453098297,
0.006839870009571314,
0.04014592617750168,
-0.09004385024309158,
0.... |
Failure\nIn general, current guideline-directed\nmedical therapy for a history of MI andsymptomatic stage C and D heart failurein people with diabetes is similar tothat for people without diabetes. Atthese advanced stages of heart failure,a collaborative approach with a cardio-\nvascular specialist is recommended. The | [
-0.0029817211907356977,
0.006856636144220829,
-0.005396955646574497,
0.038144536316394806,
-0.07908502221107483,
-0.025814572349190712,
0.012566132470965385,
0.13597865402698517,
-0.051909759640693665,
-0.08080824464559555,
-0.07818954437971115,
0.04148364067077637,
-0.02947303280234337,
0... |
vascular specialist is recommended. The\ntreatment recommendations are de-tailed in current 2022 American HeartAssociation/American College of Cardi-ology/Heart Failure Society of Americaguidelines for the management of heartfailure (210).Glucose-Lowering Medications and\nHeart Failure: Discussion of HeartFailure Outco... | [
0.04006987810134888,
0.03232564032077789,
0.04116886854171753,
0.022013919427990913,
-0.0646861344575882,
-0.07238757610321045,
-0.09726157039403915,
0.07147812843322754,
-0.06648439913988113,
-0.04095286875963211,
-0.10127396881580353,
0.027752747759222984,
-0.14003971219062805,
0.0634003... |
Heart Failure: Discussion of HeartFailure Outcomes\nData on the effects of glucose-lowering\nagents on heart failure outcomes have\ndemonstrated that thiazolidinedioneshave a strong and consistent relation-ship with increased risk of heart failure\n(283–285). Therefore, thiazolidinedione\nuse should be avoided in peopl... | [
0.017650900408625603,
0.05228406563401222,
-0.06530571728944778,
0.012113569304347038,
-0.054681260138750076,
0.0034711549524217844,
0.006942720152437687,
0.11585041135549545,
-0.05018986016511917,
0.025671973824501038,
-0.043941009789705276,
0.06901223957538605,
-0.022449687123298645,
0.0... |
use should be avoided in people with\nsymptomatic heart failure. Restrictions\nto use of metformin in people with\nmedically treated heart failure were re-moved by the FDA in 2006 (286). Obser-\nvational studies of people with type 2\ndiabetes and heart failure suggest thatmetformin users have better outcomesthan indiv... | [
-0.04277321323752403,
-0.014208710752427578,
-0.015674686059355736,
0.016823846846818924,
-0.04254445806145668,
0.015225183218717575,
-0.026012206450104713,
0.1409444659948349,
-0.012953600846230984,
-0.06936637312173843,
-0.060345012694597244,
0.10889548808336258,
-0.09329027682542801,
0.... |
hyperglycemic agents (287); however,\nno randomized trial of metformin ther-apy has been conducted in people with\nheart failure. Metformin may be used\nfor the management of hyperglycemiain people with stable heart failure as\nlong as kidney function remains within\nthe recommended range for use (288).\nRecent studies... | [
-0.04683511704206467,
-0.03548378497362137,
-0.03314896672964096,
0.01661331206560135,
-0.12243755906820297,
-0.005960872396826744,
-0.010618132539093494,
0.12378378957509995,
-0.026485953480005264,
-0.053773198276758194,
-0.05668593943119049,
0.08837029337882996,
-0.05250585451722145,
-0.... |
Recent studies examining the rela-\ntionship between DPP-4 inhibitors and\nheart failure have had mixed results.\nThe Saxagliptin Assessment of VascularOutcomes Recorded in Patients with Di-\nabetes Mellitus –Thrombolysis in Myo-\ncardial Infarction 53 (SAVOR-TIMI 53)\nstudy showed that individuals treatedwith the DPP-... | [
-0.0322367288172245,
-0.02150549180805683,
0.007199708838015795,
-0.0212355125695467,
-0.027159089222550392,
0.017339833080768585,
-0.02330932207405567,
0.17719003558158875,
-0.013819131068885326,
0.003943074494600296,
-0.07564426213502884,
0.00032350103720091283,
-0.0178084559738636,
-0.0... |
more likely to be hospitalized for heart\nfailure than those given placebo (3.5%vs. 2.8%, respectively) (289). However,\nthree other cardiovascular outcomes\ntrials—Examination of Cardiovascular Out-\ncomes with Alogliptin versus Standard of\nCare (EXAMINE) (290), Trial Evaluating | [
0.05011163279414177,
0.0055654700845479965,
-0.06468796730041504,
0.01576242782175541,
-0.02331705018877983,
-0.06962307542562485,
-0.09061865508556366,
0.1235053613781929,
0.06102732941508293,
-0.06570340692996979,
-0.008988306857645512,
0.040611907839775085,
-0.06425409764051437,
-0.0088... |
Care (EXAMINE) (290), Trial Evaluating\nCardiovascular Outcomes with Sitagliptin(TECOS) (291), and the Cardiovascular\nand Renal Microvascular Outcome Study\nWith Linagliptin (CARMELINA) (292) —did\nnotfind a signi ficant increase in risk of\nheart failure hospitalization with DPP-4\ninhibitor use compared with placebo. ... | [
-0.009628016501665115,
-0.038731638342142105,
-0.07628937810659409,
-0.0005594948306679726,
-0.0587492473423481,
-0.018001670017838478,
-0.0682535171508789,
0.18156594038009644,
0.023864801973104477,
-0.04260741546750069,
-0.06696914881467819,
0.025426555424928665,
-0.05789539963006973,
-0... |
inhibitor use compared with placebo. No\nincreased risk of heart failure hospitaliza-tion has been identi fied in the cardiovas-\ncular outcomes trials of the GLP-1receptor agonists lixisenatide, liraglutide,semaglutide, exenatide once weekly,\nalbiglutide, or dulaglutide compared\nwith placebo ( Table 10.3 B) (255,256,... | [
0.03364943712949753,
-0.052405945956707,
-0.09827136993408203,
-0.025961386039853096,
-0.02120712772011757,
-0.0048456802032887936,
-0.02753162942826748,
0.1269012689590454,
0.07308470457792282,
-0.04258095845580101,
0.002533105667680502,
0.07387340813875198,
-0.037936657667160034,
0.02104... |
with placebo ( Table 10.3 B) (255,256,\n259– 261).\nReduced incidence of heart failure\nhas been observed with the use ofSGLT2 inhibitors (11,247,249). In EMPA-REGS206 Cardiovascular Disease and Risk Management Diabetes Care Volume 47, Supplement 1, January 2024\n©AmericanDiabetesAssociation | [
0.00003928495061700232,
-0.017446007579565048,
-0.080079585313797,
0.021123729646205902,
0.0034989796113222837,
-0.03767435625195503,
-0.023987047374248505,
0.12599436938762665,
-0.0027304624672979116,
-0.07482492178678513,
-0.01820782572031021,
0.05566560849547386,
-0.012636374682188034,
... |
OUTCOME, the addition of empaglifl ozin to\nstandard care led to a signi ficant 35% re-\nduction in hospitalization for heart failure\ncompared with placebo (11). Although themajority of individuals in the study did not\nhave heart failure at baseline, this bene fit\nwas consistent in individuals with and with- | [
-0.001604245975613594,
0.03964337334036827,
-0.04787934198975563,
0.026921994984149933,
0.02609650231897831,
-0.04226381704211235,
-0.05333177000284195,
0.12308412790298462,
0.013894100673496723,
-0.07201649993658066,
0.01420736312866211,
0.03761990740895271,
-0.03278118744492531,
0.035605... |
was consistent in individuals with and with-\nout a history of heart failure (13). Similarly,in CANVAS and DECLARE-TIMI 58, there\nwere 33% and 27% reductions in hospi-\ntalization for heart failure, respectively,with SGLT2 inhibitor use versus pla-cebo (12,249). Additional data from the\nCREDENCE trial with canagli flo... | [
-0.018180765211582184,
0.02094998210668564,
-0.05098399892449379,
-0.022332772612571716,
0.025257764384150505,
0.0006507800426334143,
-0.06173945963382721,
0.11559505015611649,
-0.007886378094553947,
-0.05854744091629982,
0.04641658440232277,
0.013974800705909729,
-0.008830967359244823,
0.... |
CREDENCE trial with canagli flozin showed\na3 9 %r e d u c t i o ni nh o s p i t a l i z a t i o nf o r\nheart failure, and 31% reduction in thecomposite of cardiovascular death orhospitalization for heart failure, in a dia-\nbetic kidney disease population with\nalbuminuria (UACR >300– 5,000 mg/g)\n(247). These combine... | [
0.006613521836698055,
0.06240319460630417,
-0.07467390596866608,
-0.02651749551296234,
-0.030702365562319756,
-0.0038564966525882483,
0.015862369909882545,
0.08810027688741684,
-0.007953036576509476,
-0.035626526921987534,
-0.018442312255501747,
-0.030324123799800873,
-0.022160517051815987,
... |
(247). These combined findings from four\nlarge outcomes trials of three different\nSGLT2 inhibitors are highly consistent and\nclearly indicate robust bene fits of SGLT2\ninhibitors in the prevention of heartfailure hospitalizations. The EMPA-REG\nOUTCOME, CANVAS, DECLARE-TIMI 58, | [
-0.0450345017015934,
-0.006596459075808525,
-0.012087446637451649,
-0.02009725756943226,
0.05948657542467117,
0.028582686558365822,
-0.028066713362932205,
0.15495608747005463,
-0.0028321256395429373,
-0.01723494753241539,
0.06969484686851501,
-0.01577872596681118,
0.02012977935373783,
-0.0... |
OUTCOME, CANVAS, DECLARE-TIMI 58,\nand CREDENCE trials suggested, but didnot prove, that SGLT2 inhibitors wouldbe bene ficial in the treatment of people\nwith established heart failure. More re-\ncently, the placebo-controlled DAPA-HF\ntrial evaluated the effects of dapagli flozin | [
-0.08840373903512955,
-0.005374646279960871,
-0.07083702087402344,
0.007403376512229443,
-0.017992282286286354,
-0.016736673191189766,
-0.08365125209093094,
0.14946356415748596,
-0.05075176805257797,
-0.04728459566831589,
0.0028256296645849943,
0.056992195546627045,
-0.03634742274880409,
-... |
trial evaluated the effects of dapagli flozin\non the primary outcome of a compositeof worsening heart failure or cardiovascu-\nlar death in individuals with New York\nHeart Association (NYHA) class II, III, or IVh e a r tf a i l u r ea n da ne j e c t i o nf r a c t i o no f40% or less. Of the 4,744 trial partici- | [
0.03489791601896286,
0.04056907817721367,
-0.02674289606511593,
0.02974647656083107,
-0.026219597086310387,
-0.012380314990878105,
-0.09529004991054535,
0.12001616507768631,
-0.04688754677772522,
-0.05909409373998642,
-0.016711171716451645,
0.03718416392803192,
-0.07977156341075897,
-0.007... |
pants, 45% had a history of type 2 diabe-\ntes. Over a median of 18.2 months, thegroup assigned to dapagli flozin treatment\nhad a lower risk of the primary outcome(HR 0.74 [95% CI 0.65 –0.85]), lower risk\noffirst worsening heart failure event (HR\n0.70 [95% CI 0.59– 0.83]), and lower risk | [
0.005903095472604036,
0.07888983190059662,
-0.012779670767486095,
0.02444438263773918,
-0.0711229220032692,
-0.07289808988571167,
-0.0026022521778941154,
0.12820398807525635,
-0.08430873602628708,
-0.05092206969857216,
0.002237842418253422,
0.02370544895529747,
-0.021424077451229095,
-0.01... |
0.70 [95% CI 0.59– 0.83]), and lower risk\nof cardiovascular death (HR 0.82 [95% CI0.69–0.98]) compared with placebo. The\neffect of dapagli flozin on the primary out-\ncome was consistent regardless of thepresence or absence of type 2 diabetes(14).\nEMPEROR-Reduced assessed the ef-\nfects of empagli flozin 10 mg once da... | [
-0.025858189910650253,
0.052124377340078354,
-0.09938810020685196,
0.04358760267496109,
-0.01624714583158493,
-0.08675622195005417,
0.01967739127576351,
0.15078876912593842,
-0.009443740360438824,
-0.05688122659921646,
-0.028523484244942665,
0.017367564141750336,
-0.08537043631076813,
-0.0... |
fects of empagli flozin 10 mg once daily\nversus placebo on a primary compositeoutcome of cardiovascular death or hos-pitalization for worsening heart failure\nin a population of 3,730 individuals | [
0.019340842962265015,
0.03614864870905876,
-0.047885261476039886,
0.03242583945393562,
-0.06190190836787224,
-0.08152851462364197,
-0.0006904908805154264,
0.14736135303974152,
-0.04543308541178703,
-0.08033435046672821,
0.004582712426781654,
0.004563069902360439,
-0.007384416647255421,
-0.... |
in a population of 3,730 individuals\nwith NYHA class II, III, or IV heart failureand an ejection fraction of 40% or less(253). At baseline, 49.8% of participantshad a history of diabetes. Over a me-dian follow-up of 16 months, those inthe empagli flozin-treated group had a\nreduced risk of the primary outcome\n(HR 0.75... | [
0.056792888790369034,
0.06985071301460266,
-0.039542507380247116,
0.06814823299646378,
-0.024583932012319565,
-0.024177320301532745,
-0.0032739690504968166,
0.08591032773256302,
-0.044123098254203796,
-0.033874448388814926,
-0.02006095089018345,
0.016870887950062752,
-0.03569445386528969,
... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.